This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 452| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2286 | Glutamine amidotransferase | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.69) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2287 | Phosphoglycerate kinase 1 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.57) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2288 | TCP-1 chaperonin cofactor A | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.57) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2289 | TCP-1-gamma | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.64) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2290 | Multidrug resistance-associ ated protein MGr1-Ag | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.51) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2291 | Nuclear chloride ion channel 27 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.64) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2292 | RPS5 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 6.35) and (v/s HCV associated HCC with ratio of 2.38) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2293 | KRT8 | RNAs | Human | Upregulated in HBV associated HCC ( v/s normal with fold change 5.68) and (v/s HCV associated HCC with ratio 3.19) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2294 | CFLAR | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 2.86) and (v/s HCV associated HCC with ratio of 2.09) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2295 | ATP5F1 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 4.19) and (v/s HCV associated HCC with ratio of 3.52) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2296 | IGFBP2 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 3.37) and (v/s HCV associated HCC with ratio of 2.49) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2297 | MAP3K5 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 3.76) and (v/s HCV associated HCC with ratio of 2.33) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2298 | MMP9 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 7.43) and (v/s HCV associated HCC with ratio of 3.74) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2299 | VIM | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 8.61) and (ratio of HBV-HCC v/s HCV-HCC 0.28) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2300 | ACTB | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 4.13) and (ratio of HBV-HCC v/s HCV-HCC 0.37) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2301 | GAPD | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 5.27) and (ratio of HBV-HCC v/s HCV-HCC 0.29) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2302 | CD58 | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 4.68) and (ratio of HBV-HCC v/s HCV-HCC 0.31) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
| 2303 | CD24 | RNAs | Human | Upregulated in the high-risk group | Prognostic | Early recurrence of HCC v/s Late recurrence of HCC | p < 0.001 | Tissue | 18381945 |
| 2304 | CLDN10 | RNAs | Human | Upregulated in Cirrhosis v/s control and early and advanced HCC | Diagnostic | Cirrhosis v/s Low/High grade dysplastic nodules, normal and early/Late HCC | p < 0.05 | Tissue | 17393520 |
| 2305 | GREM2 | RNAs | Human | Upregulated in dysplasia v/s control and early/advanced HCC | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
| 2306 | EPO | RNAs | Human | Upregulated in dysplasia v/s control and early/advanced HCC | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
| 2307 | NRG1 | RNAs | Human | Upregulated in dysplasia v/s control and early/advanced HCC | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
| 2308 | ASPM | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
| 2309 | PRIM1 | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
| 2310 | HMMR | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
| 2311 | IRAK1 | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
| 2312 | C/EBP | RNAs | Human | Downregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
| 2313 | HNF-1 | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
| 2314 | HNF-3beta | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
| 2315 | HNF-4alpha | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
| 2316 | HNF-4gamma | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
| 2317 | NDRG2 | Protein and RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic and Prognostic | HCC v/s cirrhosis/healthy/non-tumor HCC; associated with recurrence and tumor grade | p < 0.05 | Tissue | 18519680 |
| 2321 | TGF beta | RNAs | Human | Upegulated in HCC than non-tumor | Prognostic | early occurrence v/s late recurrence | NA | Tissue | 20380719 |
| 2322 | Myc | RNAs | Human | Upegulated in HCC than non-tumor | Prognostic | early occurrence v/s late recurrence | NA | Tissue | 20380719 |
| 2323 | LOC388796, A_32_P406142, SAFB, MKL1, TNKS1BP1, PMM2, PPP2R5C, SAFB2, GATA4, RASD1, KIAA1967, | RNAs | Human | over expressed in subjects with fastest recurrence | Prognostic | early occurrence v/s late recurrence | p < 0.0001 | Tissue | 20380719 |
| 2324 | ID2 | Protein and RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.4) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.005 | Tissue | 17088983 |
| 2325 | API5 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.49) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2326 | CTAG1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.36) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2327 | NOLA2 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.34) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2328 | DKFZP566D193 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.3) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2329 | IMMT | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.3) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2330 | DDX1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.16) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2331 | NUDC | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2332 | HT010 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2333 | RAN | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2334 | PDHB | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.13) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2335 | SCA1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.12) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2336 | PTENP1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.11) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2337 | HFL3 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 2.0) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2338 | PMS2L11 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.83) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |